Martin DreylingExecutive Steering Committee Member

Professor Martin Dreyling is Professor of Medicine and Head of the lymphoma program in Medical Clinic III, Groβhadern Clinic, Ludwig-Maximilians-Universität, Munich, DE. He studied at the universities of Düsseldorf, Giessen, Tübingen, and Würzburg, DE, and completed his clinical training at the universities of Bonn, Münster, Göttingen, and Munich, DE. In addition, he was Visiting Scientist at the University of Chicago, US, between 1992−1995.

His scientific focus is on the molecular basis of malignant transformation, cell cycle dysregulation, and secondary genetic alterations, as well as biological prognostic factors in malignant lymphoma. He is also interested in innovative therapeutic approaches, including novel antibodies and molecular targeted approaches, like inhibitors of the B-cell receptor pathway.

Prof. Dreyling is Coordinator of the European MCL Network and Assistant Coordinator of the German Low-Grade Lymphoma Study Group. He has co-authored numerous scientific papers, book chapters, and abstracts in international peer-reviewed journals.

Positions of responsibility/awards:

• Coordinator of the European MCL Network since 2003
• On the advisory board for the German Society for Hematology and Medical Oncology (DGHO) from 2004–2017
• On the board of the German Study Group for Low-grade Malignant Lymphomas (GLSG) since 2002
• Coordinator of the Center for Malignant Hematology (HaemaKUM) since 2012
• Received the Ellen Glesby Leadership Award, 2007
• Received the Fritz Acker prize, 2015
• Received the Hermansky Award for Hematology Oncology, 2017